As of 2025-05-15, the Fair Value of ReShape Lifesciences Inc (RSLS) is -2.53 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 6.05 USD, the upside of ReShape Lifesciences Inc is -141.77%.
With the market price of 6.05 USD and our fair value calculation, ReShape Lifesciences Inc (RSLS) is not a good investment. Investing in RSLS stocks now will result in a potential loss of 141.77%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -12.33 | -63.15 | -46.21 | -11.39 | -7.13 | -28.04 |
| YoY growth | 47.93% | -412.17% | 26.83% | 75.36% | 37.38% | -44.93% |
| Market Cap (mil) | 85.35 |
| P/E | |
| Forward P/E |
| EPS | -0.51 |
| Avg earnings growth rate | -44.93% |
| TTM earnings | -7.13 |